

# SESSIONS

DAY 1 - 07/03/2023

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

7-9 March 2023  
Westin Miyako Kyoto  
Kyoto, Japan

## Registration and Coffee

08:00 - 09:00

## Co-Workshop Moderators' Welcome and Opening Remarks

09:00 - 09:15

Workshop #1: Managing CMC Activities for Complex and Emerging Oligonucleotide Therapeutics

### Participants

**Thomas Rupp** - Owner & Principal, Thomas Rupp Consulting, Germany

**Marc Lemaître, PhD** - Consultant, ML Consult

## Workshop Moderators' Opening Remarks

09:00 - 09:15

Workshop #2: Current Topics in Peptide Discovery and Development: A Focus on Improving Peptide Properties

### Workshop Overview:

This workshop will discuss a variety of strategies and techniques to improve the drug-like properties of peptides throughout the product lifecycle from discovery through development and chemical synthesis. Developability and manufacturability considerations will also be discussed. Examples and case studies from a variety of peptide programs will be presented along with challenges encountered, successes achieved and lessons learned.

### Participants

**Bruce Morimoto, PhD** - Vice President, Drug Development, Alto Neuroscience

**Robert Hagopian** - Director Business Development, PolyPeptide Group

## Workshop Agenda

09:15 - 12:45

Workshop #1: Managing CMC Activities for Complex and Emerging Oligonucleotide Therapeutics

### Workshop Overview:

This workshop will address early drug development and CMC of oligonucleotide therapeutics. Preparing for IND/IMP is a critical and strategic step for successful start of clinical development. A detailed discussion of moving oligonucleotide therapeutics from discovery to clinical trials will include a description of CMC strategies for early clinical development, process development, raw materials selection and control, GMP synthesis, analytical controls and specifications. The workshop will be split into a chemistry part from early synthesis to initial scale-up, addressing impurities and their control and a regulatory part addressing what is needed for the preparation of IND-IMP dossiers based on existing guidelines. Participants will gain a basic understanding of the considerations and requirements for taking an oligonucleotide therapeutic into first-in-human clinical trials. After the presentations the speakers will jointly chair a panel discussion on CMC aspects.

### Topics to be covered and format:

- 2 presentations, 45-minutes each followed by a 15-minute open discussion
- 30 – 60-minute panel discussion on CMC aspects
- CMC activities for complex and emerging oligonucleotide therapeutics
- Impurities and their control
- Preparation of an IND and regulatory aspects

### Who should attend?

Anyone interested in development of complex oligonucleotide therapeutics; Anyone interested in outsourcing the manufacturing of oligonucleotide therapeutics to a CMO / CRO. This includes R&D Researchers, Manufacturing Personnel, Quality Assurance, Project Management, Business Development and Scientific Management

### Participants

**Thomas Rupp** - Owner & Principal, Thomas Rupp Consulting, Germany

**Marc Lemaître, PhD** - Consultant, ML Consult

## Advantages of Using Cyclic Peptides as Therapeutics with a Focus on Improving the Properties of Therapeutic Peptides

09:15 - 10:00

Workshop #2: Current Topics in Peptide Discovery and Development: A Focus on Improving Peptide Properties

This presentation will describe why and how cyclic peptides have advantages over linear peptides in terms of biopharmaceutical properties. This will include describing various classes of cyclic peptides (including cyclotides), including their discovery, their synthesis and their applications. Key advantages include increased stability and cell permeability, and in some cases the potential for oral bioavailability.

### Participants

**David Craik, PhD** - Professor of Biomolecular Structure, Institute for Molecular Bioscience, University of Queensland

## Enhancing Peptide Properties by Side-chain and Structural Modification

10:00 - 10:45

Workshop #2: Current Topics in Peptide Discovery and Development: A Focus on Improving Peptide Properties

Peptides have highly attractive biological properties due to their target specificity, but their pharmacological properties are often less favorable. This session takes a tour through a range of structural modifications applied to peptides designed to improve properties and considers manufacturing implications of such modifications.

### Participants

**Alaric Desmarchelier, PhD** - Business Development Manager - Peptides, Almac Group

## Networking Refreshment Break

10:45 - 11:15

Workshop #2: Current Topics in Peptide Discovery and Development: A Focus on Improving Peptide Properties

# SESSIONS

DAY 1 - 07/03/2023

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

7-9 March 2023  
Westin Miyako Kyoto  
Kyoto, Japan

## Insights into Cell Penetration: Cyclic Davunetide As a Model System

11:15 - 12:00

Workshop #2: Current Topics in Peptide Discovery and Development: A Focus on Improving Peptide Properties

Davunetide is an 8-amino acid peptide that was in clinical development for the treatment of neurodegenerative diseases. The target for davunetide is intracellular, modulating microtubule dynamics. Additionally, nonclinical, and clinical pharmacokinetics confirmed it could get past the blood-brain-barrier. To better understand the mechanism by which davunetide can penetrate cell membranes and enter the brain, a series of cyclic peptides were synthesized to test various hypotheses.

### Participants

**Bruce Morimoto, PhD** - Vice President, Drug Development, Alto Neuroscience

## Current Chemical Strategies in Extending Half-Lives of Therapeutic Peptides

12:00 - 12:45

Workshop #2: Current Topics in Peptide Discovery and Development: A Focus on Improving Peptide Properties

Therapeutic peptides have been proven to be very effective in treating critical human diseases. Their number on the pharmaceutical market has significantly increased over the past two decades. Thanks to the chemical modification strategies offering to significantly extend their half live and to overcome the biggest challenge of fast degradation in serum. This presentation gives examples of chemistry applied by the CDMOs and illustrate the evolving complexity of the therapeutic peptides to ensure a long-acting effect.

### Participants

**El Djouhar Rekaï, PhD** - Head of Business Unit Peptide Process Development, PolyPeptide Group

## Close of Workshop and Luncheon for Morning Workshop Attendees

12:45 - 13:55

## Chairperson's Remarks

13:55 - 14:00

Main Conference Plenary Keynote Session

## The Display for Pseudo-Natural Products

14:00 - 14:30

Main Conference Plenary Keynote Session

### Participants

**Hiroaki Suga, Ph.D.** - Professor of Chemistry, School of Science, University of Tokyo, Japan

## RNA Therapeutics: A Versatile Drug Discovery Platform

14:30 - 15:00

Main Conference Plenary Keynote Session

In recent years, vast omics information has provided insights into the mechanisms of many diseases, common and rare. RNA therapeutics, which can directly address molecular defects, offer the potential to deliver precision medicines for diseases with significant unmet need. Here I will discuss our efforts at Ionis to develop novel RNA therapeutics for diseases of various nature.

### Participants

**Shuling Guo, PhD** - Vice President, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc.

## Using Plants as Biofactories to Produce Therapeutic Peptides

15:00 - 15:30

Main Conference Plenary Keynote Session

We are using gene-editing approaches to optimise host plants for the production of cyclic peptides. This presentation will discuss the advantages of *Nicotiana benthamiana* as producer plant for making cyclotides of therapeutic interest. Plant based production offers cost advantages and ease of scalability compared to traditional chemical peptide synthesis or cell-based manufacturing systems for peptides.

### Participants

**David Craik, PhD** - Professor of Biomolecular Structure, Institute for Molecular Bioscience, University of Queensland

## Networking Refreshment Break

15:30 - 16:00

Main Conference Plenary Keynote Session

## RNAi in the Era of Nucleic Acid-based Therapeutics

16:00 - 16:30

Main Conference Plenary Keynote Session

In this presentation, I'll cover the major milestones over last two decades that led to harnessing the power of RNAi technology for molecular medicines. The presentation will include the highlights of current clinical programs and advances in extra-hepatic delivery for expanding the scope of RNAi therapeutics.

### Participants

**Vasant Jadhav, PhD** - Senior Vice President, Head of RNAi Platform, Alnylam Pharmaceuticals

## Recent Progress in the Development of Bridged Nucleic Acids

16:30 - 17:00

Main Conference Plenary Keynote Session

Phosphorothioate (PS) linkages play an important role in the development of antisense oligonucleotides (ASOs). However, the PS linkages also have several drawbacks. One solution to the problems may be to reduce the number of PS linkages in ASOs. However, replacing PS linkages with PO linkages greatly decreases in vivo stability of ASOs. We have successfully synthesized ASOs with higher enzymatic resistance than the PS oligonucleotides while maintaining excellent activity by introducing novel nucleoside derivatives we recently developed.

### Participants

**Satoshi Obika, PhD** - Professor, Graduate School of Pharmaceutical Sciences, Osaka University

## Close of Day One

17:00 - 17:05

# SCHEDULE

DAY 1 - 07/03/2023

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

7-9 March 2023  
Westin Miyako Kyoto  
Kyoto, Japan

TIME	WORKSHOP #1: MANAGING CMC ACTIVITIES FOR COMPLEX AND EMERGING OLIGONUCLEOTIDE THERAPEUTICS	WORKSHOP #2: CURRENT TOPICS IN PEPTIDE DISCOVERY AND DEVELOPMENT: A FOCUS ON IMPROVING PEPTIDE PROPERTIES	MAIN CONFERENCE PLENARY KEYNOTE SESSION
08:00	08:00 - Registration and Coffee	08:00 - Registration and Coffee	08:00 - Registration and Coffee
09:00	09:00 - Co-Workshop Moderators' Welcome and Opening Remarks 09:15 - Workshop Agenda	09:00 - Workshop Moderators' Opening Remarks 09:15 - Advantages of Using Cyclic Peptides as Therapeutics with a Focus on Improving the Properties of Therapeutic Peptides	
10:00		10:00 - Enhancing Peptide Properties by Side-chain and Structural Modification 10:45 - Networking Refreshment Break	
11:00		11:15 - Insights into Cell Penetration: Cyclic Davunetide As a Model System	
12:00	12:45 - Close of Workshop and Luncheon for Morning Workshop Attendees	12:00 - Current Chemical Strategies in Extending Half-Lives of Therapeutic Peptides 12:45 - Close of Workshop and Luncheon for Morning Workshop Attendees	12:45 - Close of Workshop and Luncheon for Morning Workshop Attendees
13:00			13:55 - Chairperson's Remarks
14:00			14:00 - The Display for Pseudo-Natural Products 14:30 - RNA Therapeutics: A Versatile Drug Discovery Platform
15:00			15:00 - Using Plants as Biofactories to Produce Therapeutic Peptides 15:30 - Networking Refreshment Break
16:00			16:00 - RNAi in the Era of Nucleic Acid-based Therapeutics 16:30 - Recent Progress in the Development of Bridged Nucleic Acids
17:00	17:00 - Close of Day One	17:00 - Close of Day One	17:00 - Close of Day One

# SESSIONS

DAY 2 - 08/03/2023

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

7-9 March 2023  
Westin Miyako Kyoto  
Kyoto, Japan

## Registration and Coffee

08:00 - 08:40

## Chairperson's Remarks

08:40 - 08:45

Plenary Session: mRNA Therapeutics and Vaccines

## Participants

**Yogesh Sanghvi, PhD** - President, Rasayan Inc.

## mRNA Based Approach to Anti-cancer Immunotherapeutics

08:45 - 09:15

Plenary Session: mRNA Therapeutics and Vaccines

One of the biggest challenges in fighting cancer is that every patient has a unique cancer. One reasonable approach to overcome this is to target the unique molecular signature of each cancer and to adapt treatment to the patient's disease and immune system dynamics. The presentation highlights how the mRNA platform technology offers plenty of new options to deliver the genetic information of antigens into antigen-presenting dendritic cells of the immune system.

## Participants

**Tanja Auth** - Director CMC, BioNTech SE

## Analytical Comparability Strategies to Enable Rapid Development of SARS-CoV-2 Variant mRNA Vaccines

09:15 - 09:45

Plenary Session: mRNA Therapeutics and Vaccines

## Participants

**Tyler Carlage, PhD** - Fellow, Analytical Development, Moderna

## Regulatory Approval of mRNA and DNA Vaccines

09:45 - 10:15

Plenary Session: mRNA Therapeutics and Vaccines

## Participants

**Duu-Gong Wu, PhD** - Executive Director, Regulatory and CMC Consulting, PPD/ Evidera

## Networking Refreshment Break with Poster and Exhibit Viewing

10:15 - 10:55

## Chairperson's Remarks

10:55 - 11:00

mRNA Discovery and Development

## Chairperson's Remarks

10:55 - 11:00

CMC Strategies for Oligonucleotides and Peptides

## Chemical Synthesis of mRNAs Based on Efficient Capping Reaction

11:00 - 11:30

mRNA Discovery and Development

Site-specific chemical modification of mRNAs can improve their translation efficiency and stability. Therefore, it is desirable to develop a complete chemical synthesis method for chemically modified mRNA. The key step in the synthesis of eukaryotic mRNA is a chemical reaction in which a cap structure is introduced to the chemically synthesized RNA strand. We have developed a capping reaction that proceeds rapidly and quantitatively and synthesized series of chemically modified mRNAs.

## Participants

**Hiroshi Abe, PhD** - Professor, Department of Chemistry, Graduate School, Nagoya University

## Synthetic Oligonucleotides Aren't Perfect: bioZen Oligo, Paired with HRMS, Elucidates What You're Missing

11:00 - 11:30

CMC Strategies for Oligonucleotides and Peptides

The ability to understand the relative level of purity of oligonucleotides is of utmost importance for biological applications. In this presentation we are demonstrating the ability of the bioZen Oligo column to provide high quality separation of a variety of oligonucleotide types, including those for therapeutic purposes, from their synthetic impurities, to be profiled using High Resolution Mass Spectrometry. In this talk we discuss the importance of the column for this workflow and the impact of bio-inert hardware in minimizing adduct formation and non-specific binding.

## Participants

**Michael McGinley** - Director of Applications, Phenomenex, USA

## Unlimited Potential of mRNA Therapeutics for Human Health

11:30 - 12:00

mRNA Discovery and Development

mRNA therapeutics has emerged as a novel promising modality to protect us against viral infection and for cancer immunotherapy. mRNA medicines possess several advantageous features compared to authentic small molecule drugs and antibody drugs, which enables precision medicine by relatively cheaper cost. Here, I will discuss how mRNA medicine is designed to express the protein of interest efficiently to cure a variety of diseases.

## Participants

**Akiko Yanagiya, PhD** - Scientist, Arcalis

## Introduction of Oligonucleotide CDMO Services by Solid Phase Synthesis Technology

11:30 - 12:00

CMC Strategies for Oligonucleotides and Peptides

## Participants

**Kohei Himeno** - Group Leader, GMP Manufacturing Division, Ajinomoto Bio-Pharma Services

## mRNA Medicines for Treatment of Various Diseases

12:00 - 12:30

mRNA Discovery and Development

mRNA is an emerging drug modality for protein replacement therapy. Direct delivery of mRNA can be applied not only as an alternative to gene therapy but also for various common diseases such as osteoarthritis. Here I would like to present our recent trials for developing new applications of the mRNA medicines.

## Participants

**Keiji Itaka, MD, PhD** - Professor, Department of Biofunction Research, Tokyo Medical and Dental University

# SESSIONS

DAY 2 - 08/03/2023

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

7-9 March 2023  
Westin Miyako Kyoto  
Kyoto, Japan

## Nucleic Acid Therapeutics Toolbox for Modifications and Cell Delivery

12:00 - 12:30

CMC Strategies for Oligonucleotides and Peptides

Oligonucleotide-based therapies are now a validated technology and in recent years the number of FDA-approved oligonucleotide-based drugs has rapidly expanded, with many more drugs currently under development. However, oligonucleotides' stability, target affinity and cell delivery remain challenging and prevent their widespread clinical use. In this talk, we will provide an overview of the different chemical modifications used in designing nucleic acid-based drugs and how they can be utilized to improve the potency, duration, and safety of those therapies. The focus will be on cell delivery and the use of GalNAc conjugates, and we will discuss some of the most recent technologies. Moreover, we will have a look at how selecting the most appropriate solid support can ensure the manufacturing of high-quality oligonucleotide-based drugs on a large scale and at optimized costs.

### Participants

**Ralph Walker** - Global Nucleic Acid Chemistry Sales Director, LGC Biosearch Technologies

## Networking Luncheon with Poster and Exhibit Viewing

12:30 - 13:40

### Chairperson's Remarks

13:40 - 13:45

mRNA Discovery and Development

### Chairperson's Remarks

13:40 - 13:45

CMC Strategies for Oligonucleotides and Peptides

### Participants

**El Djouhar Rekaï, PhD** - Head of Business Unit Peptide Process Development, PolyPeptide Group

## Developing mRNA-Based Drugs for Infectious Diseases

13:45 - 14:15

mRNA Discovery and Development

The remarkable potency of mRNA vaccines in reducing the global burden of the ongoing COVID-19 pandemic has been a revelation. The self-transcribing and replicating RNA (STARRTM) technology combined with Arcturus Therapeutics proprietary lipid nanoparticle (LNP) delivery technology has produced a safe and effective vaccine against SARS-CoV-2 virus.

### Participants

**Pad Chivukula, Ph.D.** - Chief Scientific Officer and COO, Arcturus Therapeutics

## Implementation of Industry 4.0 Concepts for Manufacturing of Oligonucleotides and Peptides

13:45 - 14:15

CMC Strategies for Oligonucleotides and Peptides

Industry 4.0, or the fourth industrial revolution, refers to the automation and digitalization of traditional industrial processes through smart technology and integration. The "smart factory" concept within Industry 4.0 depicts a state of interconnected and interoperable machines, which are able to process data autonomously and act with very limited human decision making or intervention. The presentation will give an overview and examples about Industry 4.0 concepts along the typical manufacturing processes for TIDES drug substances at Bachem.

### Participants

**Daniel Samson, PhD** - Vice President, Head Oligonucleotides, Bachem AG

## mRNA Therapeutics for Regenerative Medicines

14:15 - 14:45

mRNA Discovery and Development

Great success of COVID-19 mRNA vaccines has opened the door for therapeutic uses of mRNA not only prophylactic uses. Local regenerative medicines may be one of the most promising applications of mRNA therapy. Our company is developing the RUNX1 mRNA therapy using our micelles as a carrier for treatment of osteoarthritis. We will update the progress of this and also discuss about other areas of interest.

### Participants

**Shiro Akinaga, PhD** - President and CEO/CSO, Nanocarrier Co.

## Developing the Toolbox for Sustainable Peptide Manufacturing

14:15 - 14:45

CMC Strategies for Oligonucleotides and Peptides

The need for sustainable manufacturing practices is a major challenge for the worldwide industry, and the pharma world is increasingly engaged in this important green transformation. For the synthesis of peptide APIs, where large amounts of hazardous waste is generated and atom efficiency is challenged, new manufacturing concepts is a necessity. The presentation will show how PolyPeptide Group is developing its manufacturing practices to meet the challenges by promoting the greenest solutions for peptide manufacturing.

### Participants

**Jon Holbech Rasmussen, Ph.D.** - Director Global Development, PolyPeptide Group

## Bespoke Oligonucleotide Synthesis Service and Partnership for Diagnostic and Therapeutic Applications

14:45 - 15:15

mRNA Discovery and Development

Biotage will present our capabilities for synthesizing highly complex and pure oligonucleotides for diagnostic, therapeutic, sequencing and gene-editing applications, and showcase how we can be your collaborative partner to produce reliable, quality oligonucleotides for your research and development without requiring your own expertise in-house. Biotage has world-leading expertise and proven commercial experience in partnering with organizations to provide consultancy and advice for the successful design, synthesis, and delivery of complex oligonucleotides.

### Participants

**Guillaume Parra, PhD** - Organic Specialist, Japan/APAC, Biotage

# SESSIONS

DAY 2 - 08/03/2023

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

7-9 March 2023  
Westin Miyako Kyoto  
Kyoto, Japan

## Exploration of PAT and Continuous Flow Applications in Peptide Synthesis

14:45 - 15:15

CMC Strategies for Oligonucleotides and Peptides

In recent years, process analytical technologies (PAT) have been increasingly applied in process chemistry. CordenPharma started the evaluation of a variety of analytical tools that could apply to inline monitoring of peptide synthesis. For example, refractometry was applied to all crucial SPPS steps, such as coupling reactions, deprotection and washing, providing highly promising results toward process optimization regarding overall time and the reduction of required solvents and reagents. This presentation will discuss the findings made by CordenPharma using new PAT from the proof of principle to the application in automated peptide synthesizers and will evaluate the impact of the scale-up on production level.

### Participants

**Matthieu Giraud, Ph.D.** - Global Director Peptide, Lipids and Carbohydrates Platforms, CordenPharma International

## Networking Refreshment Break with Poster and Exhibit Viewing

15:15 - 15:45

## ClinGuide 2.0 Agilent ClinGuide CRISPR sgRNA

15:45 - 16:15

Novel Technologies for Oligonucleotides

This talk will provide an overview into second generation technical capabilities of Agilent ClinGuide CRISPR sgRNA used for gene editing clinical applications. Insight into our advances for scalable (10-180 g) high-quality cGMP batch production, along with high resolution in process chromatographic controls. In addition, a discussion of the scenario for sequence verification options and Agilent's approach to this critical quality attribute.

### Participants

**Joe Guiles, PhD** - Head of Development - Nucleic Acid Solution Divis, Agilent Technologies

## Peptide API Manufacturing Process Optimization through QbD Strategy

15:45 - 16:15

CMC Strategies for Oligonucleotides and Peptides

Tackling critical peptide impurities poses one of the most demanding challenges to peptide API GMP manufacturing. Intercorrelation of the relevant process parameters significantly complicates the critical impurity formation and precludes the effective suppression strategies through the conventional process optimization tactics. QbD (Quality-by-Design) concept should be wielded to address those critical peptide impurities whose formation is maneuvered by underlying complex forces. Concrete case studies are exhibited in the subject talk, delineating the accomplished critical impurity tackling through QbD strategy, DOE (Design of Experiments) in particular. Employment of DMAIC (Design-Measure-Analyze-Improve-Control) cycle from Lean Six Sigma concept is also exemplified with a successful case study.

### Participants

**Yi Yang, Ph.D.** - Principal Scientist, Ferring Pharmaceuticals A/S

## Applied Technology for Oligonucleotide Process Improvement

16:15 - 16:45

Novel Technologies for Oligonucleotides

There has been an increase in the number of approved nucleic acid drugs and a growing pipeline targeting common diseases. This has led to a growing demand for oligo manufacturing with increasing larger scale, higher purity, process reliability, lower cost of goods, and lower environmental impact than ever before. This presentation will introduce the progress of Nitto Avecia's development to meet these demands. In particular, process analytical technologies for synthesis and chromatography, spray drying, and MCSGP will be discussed.

### Participants

**Masafumi Iwamoto, PhD** - Group Leader - Technology and Innovation, Nitto Denko Avecia

## CMC Development of Peptides, A Case Study

16:15 - 16:45

CMC Strategies for Oligonucleotides and Peptides

An effective CMC strategy for any peptide API should include risk mitigation approaches suitable for the intended clinical or commercial phase. The development and technology transfer of a Peptide API process (e.g. Lanreotide) will be presented as a case study in tailoring projects to specific regulatory routes or applications.

### Participants

**Christopher Martin, PhD** - Senior Director of Production API, Bachem Americas

## Late Breaking Oligonucleotide Presentation Thermo Fisher

16:45 - 17:15

Novel Technologies for Oligonucleotides

## Peptide Vaccine Formulation

16:45 - 17:15

CMC Strategies for Oligonucleotides and Peptides

### Participants

**Mimoun Ayoub, PhD** - Vice President, Global Head Sales and Key Account Management, CordenPharma International

## Networking Cocktail Reception with Poster and Exhibit Viewing

17:15 - 18:15

Please join your fellow attendees in the exhibit hall for an evening of networking while enjoying beverages and appetizers.

## Close of Day Two

18:15 - 18:20

# SCHEDULE

DAY 2 - 08/03/2023

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

7-9 March 2023  
Westin Miyako Kyoto  
Kyoto, Japan

TIME	PLENARY SESSION: MRNA THERAPEUTICS AND VACCINES	MRNA DISCOVERY AND DEVELOPMENT	CMC STRATEGIES FOR OLIGONUCLEOTIDES AND PEPTIDES	NOVEL TECHNOLOGIES FOR OLIGONUCLEOTIDES
08:00	<p>08:40 - Chairperson's Remarks</p> <p>08:45 - mRNA Based Approach to Anti-cancer Immunotherapeutics</p> <p>08:00 - Registration and Coffee</p>	<p>08:00 - Registration and Coffee</p>	<p>08:00 - Registration and Coffee</p>	<p>08:00 - Registration and Coffee</p>
09:00	<p>09:15 - Analytical Comparability Strategies to Enable Rapid Development of SARS-CoV-2 Variant mRNA Vaccines</p> <p>09:45 - Regulatory Approval of mRNA and DNA Vaccines</p>			
10:00	<p>10:15 - Networking Refreshment Break with Poster and Exhibit Viewing</p>	<p>10:55 - Chairperson's Remarks</p> <p>10:15 - Networking Refreshment Break with Poster and Exhibit Viewing</p>	<p>10:55 - Chairperson's Remarks</p> <p>10:15 - Networking Refreshment Break with Poster and Exhibit Viewing</p>	<p>10:15 - Networking Refreshment Break with Poster and Exhibit Viewing</p>
11:00		<p>11:00 - Chemical Synthesis of mRNAs Based on Efficient Capping Reaction</p> <p>11:30 - Unlimited Potential of mRNA Therapeutics for Human Health</p>	<p>11:00 - Synthetic Oligonucleotides Aren't Perfect: bioZen Oligo, Paired with HRMS, Elucidates What You're Missing</p> <p>11:30 - Introduction of Oligonucleotide CDMO Services by Solid Phase Synthesis Technology</p>	
12:00	<p>12:30 - Networking Luncheon with Poster and Exhibit Viewing</p>	<p>12:00 - mRNA Medicines for Treatment of Various Diseases</p> <p>12:30 - Networking Luncheon with Poster and Exhibit Viewing</p>	<p>12:00 - Nucleic Acid Therapeutics Toolbox for Modifications and Cell Delivery</p> <p>12:30 - Networking Luncheon with Poster and Exhibit Viewing</p>	<p>12:30 - Networking Luncheon with Poster and Exhibit Viewing</p>
13:00		<p>13:40 - Chairperson's Remarks</p> <p>13:45 - Developing mRNA-Based Drugs for Infectious Diseases</p>	<p>13:40 - Chairperson's Remarks</p> <p>13:45 - Implementation of Industry 4.0 Concepts for Manufacturing of Oligonucleotides and Peptides</p>	

# SCHEDULE

DAY 2 - 08/03/2023

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

7-9 March 2023  
Westin Miyako Kyoto  
Kyoto, Japan

TIME	PLENARY SESSION: MRNA THERAPEUTICS AND VACCINES	MRNA DISCOVERY AND DEVELOPMENT	CMC STRATEGIES FOR OLIGONUCLEOTIDES AND PEPTIDES	NOVEL TECHNOLOGIES FOR OLIGONUCLEOTIDES
14:00		<b>14:15</b> - mRNA Therapeutics for Regenerative Medicines <b>14:45</b> - Bespoke Oligonucleotide Synthesis Service and Partnership for Diagnostic and Therapeutic Applications	<b>14:15</b> - Developing the Toolbox for Sustainable Peptide Manufacturing <b>14:45</b> - Exploration of PAT and Continuous Flow Applications in Peptide Synthesis	
15:00	<b>15:15</b> - Networking Refreshment Break with Poster and Exhibit Viewing	<b>15:15</b> - Networking Refreshment Break with Poster and Exhibit Viewing	<b>15:45</b> - Peptide API Manufacturing Process Optimization through QbD Strategy <b>15:15</b> - Networking Refreshment Break with Poster and Exhibit Viewing	<b>15:45</b> - ClinGuide 2.0 Agilent ClinGuide CRISPR sgRNA <b>15:15</b> - Networking Refreshment Break with Poster and Exhibit Viewing
16:00			<b>16:15</b> - CMC Development of Peptides, A Case Study <b>16:45</b> - Peptide Vaccine Formulation	<b>16:15</b> - Applied Technology for Oligonucleotide Process Improvement <b>16:45</b> - Late Breaking Oligonucleotide Presentation Thermo Fisher
17:00	<b>17:15</b> - Networking Cocktail Reception with Poster and Exhibit Viewing	<b>17:15</b> - Networking Cocktail Reception with Poster and Exhibit Viewing	<b>17:15</b> - Networking Cocktail Reception with Poster and Exhibit Viewing	<b>17:15</b> - Networking Cocktail Reception with Poster and Exhibit Viewing
18:00	<b>18:15</b> - Close of Day Two	<b>18:15</b> - Close of Day Two	<b>18:15</b> - Close of Day Two	<b>18:15</b> - Close of Day Two

## Registration and Coffee

07:30 - 08:10

## Chairperson's Remarks

08:10 - 08:15

Plenary Session: Delivery Strategies for  
Macromolecules

## Participants

**Yogesh Sanghvi, PhD** - President, Rasayan Inc.

## Silence Therapeutics' mRNAi GOLD™ Platform and Development of an siRNA Targeting Lipoprotein(a) for Cardiovascular Disease

08:15 - 08:45

Plenary Session: Delivery Strategies for  
Macromolecules

This presentation will discuss:

- 1) The evolution of Silence Therapeutics across the last two decades and now poised for transformation with development of a proprietary GalNAc Oligonucleotide Discovery (GOLD) Pipeline;
- 2) Journey to the clinic with two mRNAi GOLD™ Platform programs for cardiovascular and hematological disorders;
- 3) Development of SLN360, a GalNAc-conjugated siRNA targeting lipoprotein(a), a novel independent genetically determined risk factor for cardiovascular disease and
- 4) Recent impressive first in human safety and efficacy data.

## Participants

**Curtis Rambaran, MD** - Vice President and Head, Clinical Science, Silence Therapeutics

## Heteroduplex Technology of Decreased CNS Toxicity and Improved Potency of Antisense Oligonucleotide by ICV/IT Injection

08:45 - 09:15

Plenary Session: Delivery Strategies for  
Macromolecules

We recently developed blood-brain-barrier penetrating heteroduplex oligonucleotide (Nat Biotech 2021). However, intrathecal injection is a gold standard route for treating CNS diseases. Acute toxicities of antisense oligonucleotide (ASO) such as sedation, convulsion, and ataxia limit drug development of ASO. We here achieved marked improvement of these acute toxicities of parent ASO by heteroduplex oligonucleotide technology (HDO) by more than 30-fold as NOAEL. In addition, we also have developed a new class of double-stranded ASO, overhanging heteroduplex oligonucleotide (ODO), which comprise the ASO strand and its complementary RNA strand with overhanging oligonucleotides. ODO enables efficient delivery to mice brain and silencing potency in neurons via the intra-cerebroventricular route compared with parent ASO. This HDO/ODO technology can open new horizon in ASO therapy for neurological diseases.

## Participants

**Takanori Yokota, MD, PhD** - Professor, Neurology and Neurological Science, Tokyo Medical and Dental University

## Use of Next Generation AAVs to Target Specific Cell types in the CNS or Nanoparticles to Enhance Drug delivery into the CNS

09:15 - 09:45

Plenary Session: Delivery Strategies for  
Macromolecules

Current adeno-associated virus (AAV) mediated gene therapy use vectors that have variable tropism for neurons and astrocytes. They typically fail to diffuse appreciable distances if injected directly into the parenchyma. We have developed next generation viral vectors that can selectively target cells of interest that have enhanced diffusion within the brain tissue. We have also used novel nanoparticles to enhance delivery of a small molecule into the CNS and demonstrated treatment effects in a mouse model of ALS.

## Participants

**Robert Bowser PhD** - Chief Scientific Officer, Barrow Neurological Institute

## Tuning Lipid Nanoparticles for Specific Applications

09:45 - 10:15

Plenary Session: Delivery Strategies for  
Macromolecules

Lipid Nanoparticles (LNP) are now well established for delivery of nucleic acids (NA) systemically to hepatocytes and for vaccine applications. However, many potential applications for diverse NA modalities exist outside of these areas. LNP with altered biodistribution can be achieved by changing route of administration, and modulating lipid composition accordingly. This presentation will describe the latest advances for hepatocyte delivery, as well as specialized LNP designed for extrahepatocyte use, with examples including compositions targeting the hepatic stellate cell, lung, muscle, and CNS.

## Participants

**Richard Holland, PhD** - Director of Chemistry, Technology Development, Genevant Sciences Corporation

## Networking Refreshment Break with Poster and Exhibit Viewing

10:15 - 10:55

## Chairperson's Remarks

10:55 - 11:00

Oligonucleotide Discovery and Development

## Chairperson's Remarks

10:55 - 11:00

Lipid Nanoparticles (LNPs) and Delivery

### An Efficient, Modular and Scalable Mitochondrial Delivery Vector System for RNA and DNA

11:00 - 11:30  
Oligonucleotide Discovery and Development

Defects of all protein-coding mitochondrial genes have been associated with mitochondrial disease in human. In addition, three major innate immune pathways, i.e., RIG-I MAVS, NLRP3, and TLR9, depend on mitochondria. The long non-coding  $\beta 2.7$  RNA of the human cytomegalovirus was described to localize to the mitochondria of mammalian cells and to bind and stabilize mitochondrial complex I. We identified four conserved structural subdomains within the  $\beta 2.7$  RNA which govern the mitochondrial targeting activity. The most active subdomain alone resembled the activity of the full-length  $\beta 2.7$  RNA. Tetrameric domain repeats arranged in tandem showed three-fold higher activity, depicting the modularity and scalability of this mitochondrial delivery vector system. Targeted mitochondrial delivery of antisense RNA triggered up to 97% knockdown of mitochondrial genes MT-ATP6/8 leading to a reduction of mitochondrial ATP levels and cell viability. Nuclear transcription of  $\beta 2.7$ -mRNA chimera triggered recombinant mitochondrial EGFP expression. Mitochondria-targeting domains attached to a single-stranded circular DNA efficiently co-delivered this 7200 nt DNA into the mitochondria. Finally, the shortest mitochondria-targeting  $\beta 2.7$  RNA-derived subdomain of 100 nt in length protected human dopaminergic neuroblastoma cells from 6-hydroxydopamine-induced reactive oxygen species in a Parkinson's disease model. This powerful mitochondrial delivery vector system can be explored towards mitochondrial gene therapy of human diseases including cancer, controlling of inflammation and immunity, and for anti-aging.

#### Participants

**Volker Patzel, Ph.D.** - Senior Lecturer, National University of Singapore

### Axolabs Extended Services Portfolio: Nucleic Acid Delivery by LNPs

11:00 - 11:30  
Lipid Nanoparticles (LNPs) and Delivery

#### Participants

**Carla Prata, PhD** - Senior Scientist Drug Delivery, LGC Axolabs

**Juergen Mueller, PhD** - Vice President of Commercial Operations, LGC Axolabs

### Conjugation of Chemical Handles and Functional Moieties to DNA during Solid Phase Synthesis with Sulfonyl Azides

11:30 - 12:00  
Oligonucleotide Discovery and Development

Labeling of oligonucleotides with dyes, targeting ligands and other moieties has become ever more essential in life-sciences. Conventionally, modifications are introduced to oligonucleotides during solid phase synthesis by special phosphoramidites functionalized with a chemical handle or the desired functional group. In this presentation, I describe a facile and inexpensive method to introduce modifications to oligonucleotides without the need for special phosphoramidites. The method is compatible with current phosphoramidite-based automated oligonucleotide synthesis and serves as an inexpensive and simple alternative to the unstable and expensive special phosphoramidites currently used for conjugation to oligonucleotides.

#### Participants

**Kurt Vesterager Gothelf, Ph.D.** - Professor, Department of Chemistry and iNANO, Aarhus University

### Fujifilm's Capabilities for LNP Formulation, Process Development, and Manufacturing Solutions

11:30 - 12:00  
Lipid Nanoparticles (LNPs) and Delivery

FUJIFILM started the CDMO business of lipid nanoparticles (LNPs) and proposes solutions for manufacturing issues of LNP in any development phases. For a research phase, we provide proprietary ionizable lipids, which enables to design appropriate LNPs for mRNA applications. For a clinical phase, we provide seamless scale-up manufacturing process. We will present our approaches and experiences focusing on key steps of CMC for the development of LNPs.

#### Participants

**Shigetomo Tsujihata** - Senior Scientist, Bio Science & Engineering Laboratory, FUJIFILM Corporation

### Recent Progress of Luxna's Chemistry Platform for Antisense Oligonucleotide Therapeutics

12:00 - 12:30  
Oligonucleotide Discovery and Development

More than 20 years have passed since 2'-4'-BNA/LNA was investigated, however no antisense therapeutics with 2'-4'-BNA/LNA has been approved. Even the 2'-4'-BNA/LNA incorporated antisense shows high potency of KD effect toward target mRNA, toxicity issue due to back bone modifications e.g., phosphorothioate is remaining to develop the antisense therapeutics. We will present our recent progress of chemistry platform which can reduce the toxicity of the antisense oligonucleotides. The platform contains bridged nucleic acids for wings and modified nucleic acids for gap such as amido-bridged nucleic acid (AmNA, the bridged structure is hydrophilic amide bond), guanidine-bridged nucleic acid (GuNA, the bridged structure has cationic guanidine moiety), 2'-O,4'-C-spirocyclopropylene-bridged nucleic acid (scpBNA, the bridged structure has hydrophobic cyclopropane ring), 5'-cyclopropane-DNA (5'-CP, the cyclopropane ring is on the 5'-C of DNA) and nucleobase modifications. The combination of our chemistry reduced toxicity (i.e., hepatotoxicity, cytotoxicity, acute neurotoxicity), without compromising KD effects. The platform will generate less-toxic antisense oligonucleotide which was not achieved by conventional 2'-4'-BNA/LNA.

#### Participants

**Tadashi Umamoto, PhD** - General Manager, Research and Development, Luxna Biotech Co., Ltd.

### Biodegradable Silica Based Delivery of RNA Therapeutics

12:00 - 12:30  
Lipid Nanoparticles (LNPs) and Delivery

DelSiTech Silica Matrix is a versatile drug delivery vehicle for complex therapeutic molecules, including oligonucleotide drugs such as aptamers and mRNA. Encapsulation of oligonucleotides in nanoporous, biodegradable silica provides an effective method for parenteral administration of oligonucleotides from few days to several months. Basic principles of the technology and case studies will be presented.

#### Participants

**Lasse Leino, PhD** - Chief Executive Officer, Adjunct Professor, DelSiTech Ltd.

### Networking Luncheon with Poster and Exhibit Viewing

12:30 - 13:40

#### Chairperson's Remarks

13:40 - 13:45  
Oligonucleotide Discovery and Development

## Chairperson's Remarks

13:40 - 13:45

Peptide Discovery and Development

## Participants

**El Djouhar Rekaï, PhD** - Head of Business Unit Peptide Process Development, PolyPeptide Group

## Impact of Guanidine-containing Backbone Linkages on Oligonucleotide Silencing, Splicing and RNA Base Editing Modalities

13:45 - 14:15

Oligonucleotide Discovery and Development

Chemically modified oligonucleotides hold great promise for treating genetically defined diseases. Wave generates stereopure oligonucleotides—those in which the chiral configuration of backbone linkages is precisely controlled at each position—to maximize the activity benefits realized by tuning chemistry throughout the oligonucleotide. We have recently expanded our repertoire of backbones and have developed the capabilities necessary to support synthesis of stereopure oligonucleotides incorporating these guanidine-containing linkages (PN). We have applied these synthetic capabilities across multiple oligonucleotide modalities, including silencing with RNase H or RNA interference, splicing and RNA base editing. We highlight how the PN backbone conveys substantial potency and durability benefits across modalities in preclinical animal models in multiple tissues.

## Participants

**Naoki Iwamoto, PhD** - Senior Director, Platform Discovery Sciences, Wave Life Sciences

## The Potential and Current Application of Artificial Intelligence in Peptide Drug Discovery

13:45 - 14:15

Peptide Discovery and Development

The lecture will briefly cover past and current techniques and. An emphasis will be made on the characteristics and limitation of "Display" technologies that are currently leading most peptide discovery efforts. Current discovery needs have shifted mainly from modification/optimization of natural peptide hormones to the discovery of completely novel peptides for a given target, this task is of significant complexity and is greatly increased when non-natural amino acids and different cyclization methods are required. The potential of Machine Learning/Artificial Intelligence (ML/AI) enabled peptide design/discovery is focused on the capability of specifically tailoring active peptides to prespecified binding pocket while using different non-natural building blocks and cyclization methods. Moreover, ML/AI approach has the potential of reducing the failure rate of discovery development projects by pre-rejecting problematic peptides solutions. The application of ML/AI in a specific case study for the discovery of IL-17 protein interaction inhibitor (PPI) will be discussed.

## Participants

**Immanuel Lerner, PhD** - CEO, Pepticom Ltd

## Chemical Approaches for Improving Properties of RNA Therapeutics

14:15 - 14:45

Oligonucleotide Discovery and Development

Advancements in the chemical design of oligonucleotide drugs have improved potency, safety and duration leading to better clinical outcomes. Efforts to expand the boundaries of existing chemical space to further enhance the properties of RNA therapeutics will be presented.

## Participants

**Thazha P. Prakash, Ph.D.** - Executive Research Fellow, Ionis Pharmaceuticals

## Genetically-encoded Discovery of Macrocyclic and Bicyclic Inhibitors for Difficult-to-Drug Targets

14:15 - 14:45

Peptide Discovery and Development

Billion-scale genetically-encoded (GE) libraries of polypeptides made of 20 natural amino acids are readily available but have limited structural diversity and practical utility for drug discovery. These peptides can be transformed to useful structures via "late stage" diversification using organic reactions in water. Each transformation, when optimized, can routinely convert billion starting materials to billion products at once. My talk will highlight recent development and utility of chemically-diversified GE macrocyclic libraries for drug discovery for "undruggable targets". Examples include (i) Macrocyclic structures that antagonize integrin signaling involved in inflammation in gastrointestinal tract; (ii) libraries of macrocycles with covalent warheads that yields inhibitors for targets such as PKM2; (iii) bicyclic antagonists of previously undruggable extracellular targets: immunomodulatory receptors from sialic acid-binding immunoglobulin-type of lectin (Siglec) family.

## Participants

**Ratmir Derda, PhD** - Associate Professor, Department of Chemistry, University of Alberta

## mxRNA™: Miniaturized RNAi Triggers Composed Of Single Oligonucleotides

14:45 - 15:15

Oligonucleotide Discovery and Development

Sirnaomics has developed proprietary GalNAc-RNAi therapeutic platform – GalAhead™, with mxRNA™ comprising one of its key technological components. mxRNAs (miniaturized RNAi triggers) are composed of single 30-33 nt long oligonucleotides and demonstrate excellent activity in primary hepatocytes (in vitro) and in mice (in vivo). In addition to the experiments in vitro and with rodents, we will present results of our 26-week study in non-human primates conducted with the candidate molecule for our frontrunner GalAhead™ therapeutic program, aimed to downregulate blood clotting Factor XI. We will also provide a progress report on our other GalAhead™ technologies and programs.

## Participants

**Dmitry Samarsky, PhD** - Chief Technology Officer, Sirnaomics

# SESSIONS

DAY 3 - 09/03/2023

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

7-9 March 2023  
Westin Miyako Kyoto  
Kyoto, Japan

## Bicycles – A Versatile Drug Modality for Precision-guided Therapeutics

14:45 - 15:15

Peptide Discovery and Development

Bicycles (constrained, bicyclic peptides) are highly effective at engaging target proteins selectively and with high affinity. Their favourable PK properties enable a range of routes of administration and their small size and stability allow them to penetrate tissues effectively. In addition to acting as potent pharmaceutical agents, they also make excellent delivery vehicles for targeted therapies. Bicycles are being developed for a range of applications that utilise their unique properties.

### Participants

**Liu Hong Chen, PhD** - Vice President, Discovery, Bicycle Therapeutics

## Networking Refreshment Break with Poster and Exhibit Viewing

15:15 - 15:45

## Anti-FGF2 Aptamer Therapy for Wet Age-Related Macular Degeneration and Achondroplasia

15:45 - 16:15

Oligonucleotide Discovery and Development

RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2 activity. Intravitreal administration of RBM-007 in animals demonstrated anti-angiogenic and anti-scarring effects, consistent with a therapeutic effect desired in the treatment of wet AMD. We have completed phase II clinical trials early in 2022 in the US, showing the efficacy (POC) in treatment-naïve wet AMD. RBM-007 is also effective to cure Achondroplasia (ACH) in animal models. ACH is the most prevalent genetic form of dwarfism in humans, caused by activating mutation in FGFR3 tyrosine kinase. We have successfully completed phase I study and plan to initiate early phase II study of RBM-007 for ACH in 2022.

### Participants

**Yoshikazu Nakamura, PhD** - President and CEO, Ribomic Inc

## Modulation of Lymphocyte Potassium Channel KV1.3 by Membrane-penetrating, Joint-targeting Immunomodulatory Plant Defensin

15:45 - 16:15

Peptide Discovery and Development

We describe a cysteine-rich, membrane-penetrating, joint-targeting, and remarkably stable peptide, EgK5, that modulates voltage-gated KV1.3 potassium channels in T lymphocytes by a distinctive mechanism. EgK5 enters plasma membranes and binds to KV1.3, causing current rundown by a phosphatidylinositol 4,5-bisphosphate-dependent mechanism. EgK5 exhibits selectivity for KV1.3 over other channels, receptors, transporters, and enzymes. EgK5 suppresses antigen-triggered proliferation of effector memory T cells, a subset enriched amongst pathogenic autoreactive T cells in autoimmune disease. PET-CT imaging with 18F-labeled EgK5 shows accumulation of the peptide in large and small joints of rodents. In keeping with its arthrotropism, EgK5 treats disease in a rat model of rheumatoid dermatitis. It was also effective in treating disease in a rat model of atopic dermatitis. No signs of toxicity are observed at 10-100 times the in vivo dose. EgK5 shows promise for clinical development as a therapeutic for autoimmune diseases.

### Participants

**Michael Pennington, PhD** - Chief Scientific Officer, AmbioPharm, Inc.

## Implantable Aptamer Target Therapy to Prevent Tumor Recurrence and Eliminate Metastases

16:15 - 16:45

Oligonucleotide Discovery and Development

We have developed an implantable target cancer therapy that shows very remarkable survival rate by preventing recurrence and metastasis in pancreatic cancer and TNBC animal models with very poor prognosis after surgery.

### Participants

**Jung Hwan Lee, PhD** - CEO, Interoligo Corp.

## Immunogenicity of Therapeutic Proteins: Twenty-five Years of Lessons from the Field

16:15 - 16:45

Peptide Discovery and Development

Immunogenicity of protein therapeutics was not well appreciated in the early stages of development of therapeutic proteins and led to failure to develop lifesaving or highly effective therapeutics or, following approval, to serious safety issues as well as tragic loss of efficacy. From many years of experience in the field, this seminar will highlight key examples that have spurred development of immunogenicity guidances to better assure that lifesaving, and highly effective therapeutic proteins remain safe and effective. The seminar will also highlight immunogenicity risk assessment tools and mitigation strategies to better ensure robust development of novel therapeutic proteins addressing unmet medical need.

### Participants

**Annie De Groot, MD** - Founder, CEO and CSO, EpiVax, Inc.

## Therapeutic Development Using Chemically Modified Asymmetric siRNAs

16:45 - 17:15

Oligonucleotide Discovery and Development

RNA interference (RNAi)-based gene silencing has become the 3rd therapeutic development platform with multiple FDA-approved RNAi drugs on market. OliX's asymmetric siRNA (asiRNA) triggers efficient target gene silencing with reduced non-specific effects. OliX Pharmaceuticals has developed lipid-conjugated cp-asiRNA for local administration therapeutics, and GalNAc-asiRNA for liver targeting therapeutics. I will describe OliX Pharmaceuticals' pre-clinical and clinical developments against various disease indications including (1) local administration therapeutics such as skin scar, androgenic alopecia, and age-related macular degeneration, (2) liver therapeutics such as hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), and diabetes.

### Participants

**Dong-Ki Lee, PhD** - CEO, OliX Pharmaceuticals

## Regulatory Considerations in the Development of Peptide Drugs

16:45 - 17:15

Peptide Discovery and Development

### Participants

**David Lin, PhD** - President and Principal Consultant, TS Pharma Experts LLC

## Close of Conference

17:15 - 17:20

# SCHEDULE

DAY 3 - 09/03/2023

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

7-9 March 2023  
Westin Miyako Kyoto  
Kyoto, Japan

TIME	PLENARY SESSION: DELIVERY STRATEGIES FOR MACROMOLECULES	OLIGONUCLEOTIDE DISCOVERY AND DEVELOPMENT	LIPID NANOPARTICLES (LNPS) AND DELIVERY	PEPTIDE DISCOVERY AND DEVELOPMENT
07:00	07:30 - Registration and Coffee	07:30 - Registration and Coffee	07:30 - Registration and Coffee	07:30 - Registration and Coffee
08:00	08:10 - Chairperson's Remarks 08:15 - Silence Therapeutics' mRNAi GOLD™ Platform and Development of an siRNA Targeting Lipoprotein(a) for Cardiovascular Disease 08:45 - Heteroduplex Technology of Decreased CNS Toxicity and Improved Potency of Anti-sense Oligonucleotide by ICV/IT Injection			
09:00	09:15 - Use of Next Generation AAVs to Target Specific Cell types in the CNS or Nanoparticles to Enhance Drug delivery into the CNS 09:45 - Tuning Lipid Nanoparticles for Specific Applications			
10:00	10:15 - Networking Refreshment Break with Poster and Exhibit Viewing	10:55 - Chairperson's Remarks 10:15 - Networking Refreshment Break with Poster and Exhibit Viewing	10:55 - Chairperson's Remarks 10:15 - Networking Refreshment Break with Poster and Exhibit Viewing	10:15 - Networking Refreshment Break with Poster and Exhibit Viewing
11:00		11:00 - An Efficient, Modular and Scalable Mitochondrial Delivery Vector System for RNA and DNA 11:30 - Conjugation of Chemical Handles and Functional Moieties to DNA during Solid Phase Synthesis with Sulfonyl Azides	11:00 - Axolabs Extended Services Portfolio: Nucleic Acid Delivery by LNPs 11:30 - Fujifilm's Capabilities for LNP Formulation, Process Development, and Manufacturing Solutions	

# SCHEDULE

DAY 3 - 09/03/2023

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

7-9 March 2023  
Westin Miyako Kyoto  
Kyoto, Japan

TIME	PLENARY SESSION: DELIVERY STRATEGIES FOR MACROMOLECULES	OLIGONUCLEOTIDE DISCOVERY AND DEVELOPMENT	LIPID NANOPARTICLES (LNPS) AND DELIVERY	PEPTIDE DISCOVERY AND DEVELOPMENT
12:00	12:30 - Networking Luncheon with Poster and Exhibit Viewing	12:00 - Recent Progress of Luxna's Chemistry Platform for Antisense Oligonucleotide Therapeutics 12:30 - Networking Luncheon with Poster and Exhibit Viewing	12:00 - Biodegradable Silica Based Delivery of RNA Therapeutics 12:30 - Networking Luncheon with Poster and Exhibit Viewing	12:30 - Networking Luncheon with Poster and Exhibit Viewing
13:00		13:40 - Chairperson's Remarks 13:45 - Impact of Guanidine-containing Backbone Linkages on Oligonucleotide Silencing, Splicing and RNA Base Editing Modalities		13:40 - Chairperson's Remarks 13:45 - The Potential and Current Application of Artificial Intelligence in Peptide Drug Discovery
14:00		14:15 - Chemical Approaches for Improving Properties of RNA Therapeutics 14:45 - mxRNA™: Miniaturized RNAi Triggers Composed Of Single Oligonucleotides		14:15 - Genetically-encoded Discovery of Macrocyclic and Bicyclic Inhibitors for Difficult-to-Drug Targets 14:45 - Bicycles – A Versatile Drug Modality for Precision-guided Therapeutics
15:00	15:15 - Networking Refreshment Break with Poster and Exhibit Viewing	15:45 - Anti-FGF2 Aptamer Therapy for Wet Age-Related Macular Degeneration and Achondroplasia 15:15 - Networking Refreshment Break with Poster and Exhibit Viewing	15:15 - Networking Refreshment Break with Poster and Exhibit Viewing	15:45 - Modulation of Lymphocyte Potassium Channel KV1.3 by Membrane-penetrating, Joint-targeting Immunomodulatory Plant Defensin 15:15 - Networking Refreshment Break with Poster and Exhibit Viewing
16:00		16:15 - Implantable Aptamer Target Therapy to Prevent Tumor Recurrence and Eliminate Metastases 16:45 - Therapeutic Development Using Chemically Modified Asymmetric siRNAs		16:15 - Immunogenicity of Therapeutic Proteins: Twenty-five Years of Lessons from the Field 16:45 - Regulatory Considerations in the Development of Peptide Drugs
17:00	17:15 - Close of Conference	17:15 - Close of Conference	17:15 - Close of Conference	17:15 - Close of Conference